This morning, Aphria announced it had entered into a $6.5-million deal to acquire 360,000 square feet of existing production space, located on 36 acres of land in Leamington, Ontario from its co-founder and COO Cole Cacciavillani.
“As we continue to exceed our revenue and profitability expectations, it is essential to secure both near-term and long-term capacity growth on our existing site,” said CEO Vic Neufeld. “The assets purchased lay the foundation for Aphria to remain an industry leader in Canadian medical marijuana as oil extraction comes on stream and the recreational marijuana market becomes legislated.”
Atkinson, who notes the acquired capacity that Aphria announced is slightly larger than Canopy’s Tweed Farms 350,000-sq.ft. greenhouse in Niagara-on-the-Lake, says this deal firmly places the company in the top tier of producers.
“Aphria is already an industry leader in terms of production cost, profitability, registered clients, and sales volume,” says Atkinson. “This deal ticks the last box – scale of production facilities – to have Aphria now considered truly on equal footing with Canopy as the two top players in the Canadian MMJ sector and we would argue Aphria is more attractive than Canopy due to its much higher profitability.”
In a research update to clients today, Atkinson maintained his “Buy” rating and one-year target of $2.25 on APH.
Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]
It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]
Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]
Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]
It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]
Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]
View Comments
As a patient myself, and the care giver for my mother who also tried Aphria products; I would never buy from them again! It was the worst product I have ever used.
The product was pushed way past maturity date and was substandard on both attempts to obtain decent product. We have never ordered again and have found a much better supplier.
Wow i have never tried them. But so far mettrum and aurora have done good for me.
I would think all are subject to the same quality standards? But im new.